237 related articles for article (PubMed ID: 32012325)
1. Characterizing Hepatitis C Virus-Specific CD4
Hartnell F; Esposito I; Swadling L; Brown A; Phetsouphanh C; de Lara C; Gentile C; Turner B; Dorrell L; Capone S; Folgori A; Barnes E; Klenerman P
Hepatology; 2020 Nov; 72(5):1541-1555. PubMed ID: 32012325
[TBL] [Abstract][Full Text] [Related]
2. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
[TBL] [Abstract][Full Text] [Related]
3. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Kelly C; Swadling L; Capone S; Brown A; Richardson R; Halliday J; von Delft A; Oo Y; Mutimer D; Kurioka A; Hartnell F; Collier J; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Di Marco S; Siani L; Traboni C; Hill AV; Colloca S; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Hepatology; 2016 May; 63(5):1455-70. PubMed ID: 26474390
[TBL] [Abstract][Full Text] [Related]
5. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
Callendret B; Eccleston HB; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
Hepatology; 2016 May; 63(5):1442-54. PubMed ID: 26513111
[TBL] [Abstract][Full Text] [Related]
6. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
7. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.
Lin Y; Kwon T; Polo J; Zhu YF; Coates S; Crawford K; Dong C; Wininger M; Hall J; Selby M; Coit D; Medina-Selby A; McCoin C; Ng P; Drane D; Chien D; Han J; Vajdy M; Houghton M
J Virol; 2008 Aug; 82(15):7492-503. PubMed ID: 18508900
[TBL] [Abstract][Full Text] [Related]
8. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.
Hartlage AS; Dravid P; Walker CM; Kapoor A
PLoS Pathog; 2021 Mar; 17(3):e1009391. PubMed ID: 33735321
[TBL] [Abstract][Full Text] [Related]
10. Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
Swadling L; Halliday J; Kelly C; Brown A; Capone S; Ansari MA; Bonsall D; Richardson R; Hartnell F; Collier J; Ammendola V; Del Sorbo M; Von Delft A; Traboni C; Hill AV; Colloca S; Nicosia A; Cortese R; Klenerman P; Folgori A; Barnes E
Vaccines (Basel); 2016 Aug; 4(3):. PubMed ID: 27490575
[TBL] [Abstract][Full Text] [Related]
11. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus.
Mekonnen ZA; Grubor-Bauk B; English K; Leung P; Masavuli MG; Shrestha AC; Bertolino P; Bowen DG; Lloyd AR; Gowans EJ; Wijesundara DK
J Virol; 2019 Oct; 93(19):. PubMed ID: 31292249
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
[TBL] [Abstract][Full Text] [Related]
14. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.
Wedemeyer H; He XS; Nascimbeni M; Davis AR; Greenberg HB; Hoofnagle JH; Liang TJ; Alter H; Rehermann B
J Immunol; 2002 Sep; 169(6):3447-58. PubMed ID: 12218168
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.
Zabaleta A; Llopiz D; Arribillaga L; Silva L; Riezu-Boj JI; Lasarte JJ; Borrás-Cuesta F; Prieto J; Sarobe P
Mol Ther; 2008 Jan; 16(1):210-7. PubMed ID: 17923840
[TBL] [Abstract][Full Text] [Related]
17. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
18. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein].
Guan J; Deng Y; Chen H; Yang Y; Wen B; Tan W
Bing Du Xue Bao; 2015 Jan; 31(1):7-13. PubMed ID: 25997323
[TBL] [Abstract][Full Text] [Related]
20. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
